Generated by AI
Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.
Website200 Penobscot Drive
Redwood City, CA, 94063
United States
The latest articles about CDXS.
Codexis Inc (CDXS) posted $19.3 million in Q3 2026 revenue, its fourth straight on-target quarter, while advancing enzymatic oligonucleotide manufacturing and extending its cash runway through 2028.
Summary of Nov 13's posts. Generated by AI.
Summary of Jun 18's posts. Generated by AI.
Summary of Jul 24's posts. Generated by AI.
Investors talking about CDXS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.